Avanzanite Bioscience Raises €32M In Series A Round

The Series A round was led by MVM Partners. Avanzanite Bioscience plans to use the funding to expand its pan-European infrastructure and support the development and launch of both current and future rare disease therapies.

Founded by CEO Adam Plich, Avanzanite helps biotech and pharmaceutical companies launch rare disease medicines across Europe. By combining commercial and scientific expertise with capabilities in market access, pricing, and reimbursement, the company supports innovators in bringing treatments to patients across all 32 European markets.

The company’s current portfolio includes three medicines in nephrology, ophthalmology, and haematology, with licensing or distribution rights across the European Economic Area, the UK, and Switzerland.

Read Also - Condukt Launches From Stealth With $10M To Drive Next-Gen Compliance

“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite,” said Adam Plich, Founder and CEO of Avanzanite. “With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey,” concluded Plich.

Since 1997, MVM has invested in high-growth healthcare companies worldwide. With teams in Boston, London, and the San Francisco Bay Area, the firm takes a global approach across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other key healthcare sectors.

Dr. Jack Tanaka, Partner at MVM commented, “For years MVM has watched promising rare disease medicines struggle to find a path to patients - Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”

About Avanzanite Bioscience

Founded in 2022 and based in Amsterdam, Avanzanite partners with biotech and pharma innovators to transform the launch of rare disease medicines across Europe. Leveraging deep market access expertise the company navigates complex regulatory landscapes, ensuring patients receive treatments while helping innovators successfully bring breakthrough orphan therapies to market.